Gilead Sciences Inc
NASDAQ: GILD
$89.88
+$0.74 (+0.8%)
Closing Price on January 10, 2025
GILD Articles
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
Gilead Sciences saw a sell-off after the company posted less than favorable earnings, but one analyst thinks that investors have spoken too soon.
Published:
Last Updated:
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday morning include Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital and Whiting Petroleum.
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue...
Published:
Last Updated:
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical...
Published:
Last Updated:
In a recent report, UBS made some significant changes to its Equity Focus list. The analysts look to go a touch more aggressive with the new additions.
Published:
Last Updated:
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
Published:
Last Updated:
Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.
Published:
Last Updated:
Argus reiterated Gilead Sciences as Buy, but hat really matters here is that Argus has a $150 price target on the stock.
Published:
Last Updated:
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Here are two big biopharmas, both with multibillion dollar portfolios and both of which have lost a combined $113 billion in market cap since August.
Published:
Last Updated:
Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.